Mosunetuzumab (BTCT4465A)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Mosunetuzumab (BTCT4465A), covering 2024-12-18 to 2024-12-18. Get the full timeline:
Most recent: Clinical Trial Update: A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]